Wright Medical gets FDA reclassification decision
This article was originally published in Clinica
Resorbable calcium salt used to fill bony voids or gaps of the extremities, spine and pelvis has been classified by the FDA as a class II, or medium-risk, device subject to special control. The special control is adherence to a new guidance document on the product, the agency said.
You may also be interested in...
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.
In a final guidance from the US agency, regulators say most combination product questions are best resolved through traditional pathways and noted that initiating a so-called combination product agreement meeting may be unproductive.
Metabesity is a complex issue that will require a multi-disciplinary approach, concerted effort and clear regulatory pathway to achieve solutions.